{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"17","value":"7"},{"groupId":"OG001","lowerLimit":"5","upperLimit":"27","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Distant Metastases failure time is defined as time from registration to date of distant disease, death without distant metastases (competing risk), or last known follow-up (censored) and is estimated by the cumulative incidence method. Para-aortic nodal disease is considered to be distant disease for a cervical primary, but not for an endometrial primary.","dispersionType":"95% Confidence Interval","groups":[{"description":"Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT)","id":"OG000","title":"Endometrial Cancer: IMRT"},{"description":"Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) + Chemotherapy (cisplatin)","id":"OG001","title":"Cervical Cancer: IMRT + Chemotherapy (Cisplatin)"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From registration to five years","title":"Rate of Distant Metastases at Five Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}